GLP-1 Drugs Boost Heart Health After Attack, Blockages
New findings suggest expanded role for diabetes medication in cardiovascular care
New research presented at the ASPC 2025 Congress on CVD Prevention in Boston indicates that GLP-1 receptor agonists significantly improve outcomes for patients recovering from ST-elevation myocardial infarction (STEMI) and those living with coronary plaque. These findings could redefine the use of these medications beyond diabetes and obesity management, potentially enhancing survival rates for a broader patient population.
Reduced Cardiovascular Events
A retrospective analysis of electronic health records between January 2022 and December 2024 focused on patients with diagnosed coronary plaque. In this study, individuals treated with GLP-1s demonstrated a markedly lower incidence of major adverse cardiovascular events (34.3% versus 41.9%) and myocardial infarctions (13.9% versus 20.8%) compared to non-users. Researchers noted improved lipid profiles and higher 1-year event-free survival among GLP-1 users.
Benefits Seen Post-STEMI
Similar positive results emerged from a separate study examining patients after experiencing STEMI. This analysis, also drawing on data from the TriNetX network, found that GLP-1 users had a significant reduction in hospital readmissions within 30 days (9.3% versus 12.7%). Furthermore, the GLP-1 cohort experienced fewer major adverse cardiovascular events (57.2% versus 66.7%) and recurrent heart attacks (41.2% versus 53.2%).
In a testament to their growing impact, GLP-1 medications are now recognized for their role in managing cardiovascular risk, a development that aligns with broader health trends. For instance, the prevalence of cardiovascular disease in the United States remains a significant public health challenge, with over 697,000 deaths attributed to heart disease in 2022 alone, according to the CDC (CDC, 2024).
Promising Future for GLP-1s
The collective findings from both studies suggest that GLP-1 receptor agonists offer a promising new therapeutic avenue for patients with cardiovascular conditions. By improving outcomes and survival in high-risk populations, these drugs may represent a significant advancement in the ongoing fight against heart disease.
